CureVac has filed for an initial public offering in the US, 20 years after being spun out of Eberhard Karls University of Tübingen.
CureVac, a Germany-based messenger RNA (mRNA) drug developer spun out of Eberhard Karls University of Tübingen, on Friday filed for an initial public offering on the Nasdaq Global Market with a placeholder target of $100m.
The company has not yet set any terms for the proposed offering.
Founded in 2000, CureVac is working on treatments that exploit mRNA to create immunotherapies aimed at diseases including cancer, as well as vaccines for infectious diseases such as rabies and Covid-19.
Proceeds from the offering would go towards the development of CureVac’s lead asset – CV8102, aimed at solid tumours – and a rabies vaccine, CV7202, through the completion of phase 2 trials.
Some of the money would support the clinical development of CureVac’s vaccine against Sars-CoV-2, the coronavirus that causes Covid-19, through the completion of a phase 2 study.
The remainder would drive other clinical and…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
